UDP-glycosyltransferase 3A1 (UGT3A1)

UDP-glycosyltransferase 3A1 (UGT3A1) is an enzyme of the glycosyltransferase superfamily, functioning primarily as a phase II metabolic enzyme that catalyzes the transfer of glycosyl groups from nucleotide sugars (such as UDP-glucose or UDP-N-acetylglucosamine) to small molecule substrates. This enzymatic activity is part of the body's detoxification system, aiding in the conjugation and elimination of various endogenous and exogenous substances through glucosidation and glycosylation. Unlike the more common UGT1A and UGT2B families associated with glucuronidation, UGT3A1 uses glucose and N-acetylglucosamine as donor molecules rather than glucuronic acid. UGT3A1 is expressed in human tissues such as the liver and kidney and may influence the metabolism of certain drugs, steroids, and xenobiotics. Dysregulation or genetic variants in UGT3A1 can affect drug response and toxicity, though it is not currently a primary therapeutic target. Its function in drug metabolism and disposition, along with potential links to disease and variability in drug handling, make it of clinical and pharmacogenetic interest[3].

Other names

UDP-glucuronosyltransferase 3A1UDPGT 3A1FLJ34658UDP glycosyltransferase 3 family, polypeptide A1

Glucosidation of xenobiotics and other small molecules, sometimes increasing solubility and enhancing excretion